Alnylam Pharmaceuticals
ALNY
#634
Rank
โ‚น2.822 T
Marketcap
โ‚น21,806
Share price
0.43%
Change (1 day)
75.48%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Revenue for Alnylam Pharmaceuticals (ALNY)

Revenue in 2024 (TTM): โ‚น189.04 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is โ‚น195.26 Billion. an increase over the revenue in the year 2023 that were of โ‚น152.20 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Alnylam Pharmaceuticals from 2004 to 2024

Annual revenue

Year Revenue Change
2024 โ‚น192.86 B26.72%
2023 โ‚น152.20 B77.3%
2022 โ‚น85.84 B36.61%
2021 โ‚น62.84 B74.34%
2020 โ‚น36.04 B130.01%
2019 โ‚น15.67 B199.19%
2018 โ‚น5.23 B-8.77%
2017 โ‚น5.74 B79.14%
2016 โ‚น3.20 B17.34%
2015 โ‚น2.73 B-14.77%
2014 โ‚น3.20 B9.97%
2013 โ‚น2.91 B-20.24%
2012 โ‚น3.65 B-16.55%
2011 โ‚น4.37 B-2.34%
2010 โ‚น4.48 B-3.9%
2009 โ‚น4.66 B0.92%
2008 โ‚น4.62 B131.4%
2007 โ‚น1.99 B67.47%
2006 โ‚น1.19 B363.7%
2005 โ‚น0.25 B38.83%
2004 โ‚น0.18 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚น0.21 B-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.233 T 531.69%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น142.46 B-27.04%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น61.78 B-68.36%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.492 T 2,200.55%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น4.647 T 2,279.95%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น1.436 T 635.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel